Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on 4D PHARMA PLC. We currently have 3 research reports from 1 professional analysts.
|09Nov16 04:40||RNS||Second Price Monitoring Extn|
|09Nov16 04:35||RNS||Price Monitoring Extension|
|08Nov16 04:40||RNS||Second Price Monitoring Extn|
|08Nov16 04:35||RNS||Price Monitoring Extension|
|19Oct16 04:40||RNS||Second Price Monitoring Extn|
|19Oct16 04:35||RNS||Price Monitoring Extension|
|30Sep16 07:00||RNS||Interim results for the period ended 30 June 2016|
Frequency of research reports
Research reports on
4D PHARMA PLC
4D PHARMA PLC
US pharma deals but don’t forget the rest!
09 Mar 15
While Abbvie and Pharmacyclics work out their $21bn nuptial party arrangements, there has also been some positive news over here on the UK biotech scene. British biotech company Heptares, has been bought by Japan’s Sosei in a deal worth around £250m. Which if you had not just read the $21bn number would seem like a result. This for just two COPD products, but then it has been ‘just’ hard slog since the 1990s to get to this place. Astra Zeneca signed a three year deal with Orca Pharmaceuticals for its Auto-immune program to the tune of $122m which has taken considerably less time, and overall there are definitely signs of life across the sector. So much so that Messrs Woodford and Mellon have also announced plans to invest in a significant way.
Venture life helps the Chinese Aged, SQS gets on the Italian Job, what next for Next 15
03 Feb 15
DDDD placing, ABC acquisition, ABDP new contract win, BMK preliminary results, CYAN £1m order, EKF collaboration, EMIS contract award, FPM new exploration licences, FITB joins Jawbone, partners with Cancer Research UK and court case judgement, GFM production update, HAYT £3m secured loan note programme and contract win, LWRF preliminary results, NFC proposed placing and trading update, SQS acquisition, STAF full year results, VLG distribution deal .
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 29-11-2016
29 Nov 16
Vp has reported another impressive set of interims, confirming strong growth in most markets and a positive outlook. Recent acquisitions are bedding in well and the full year outturn is set to exceed previous expectations (5%/6% EPS upgrades in FY17/FY18). The recent Capital Markets Day provided a reminder of Vp’s qualities (specialist focus, high returns, strong cash generation) and its growth potential, which in our view are not reflected in a modest <11x P/E rating. We firmly believe the shares are due a re-rating and see intrinsic value in excess of 800p.
Food intolerance driving growth
29 Nov 16
Omega Diagnostics Group has an established core business providing high quality in vitro diagnostic tests within three core areas of competence – Food Intolerance, Allergy & Autoimmune, Infectious Disease – that are sold in over 100 countries. The group offers steady low single-digit growth which is profitable and cash generative. Investment in new products has seen the launch of a new panel of automated allergy tests and progress on Visitect CD4 for monitoring of HIV positive patients. Interim results highlighted the opportunities to accelerate growth of the business, particularly Allersys, which has drawn attention from its partner.
Small Cap Breakfast
29 Nov 16
Asia Pacific Investment Partner - the research-driven emerging and frontier markets real estate development business intends to float on AIM and conduct a placing in December RM Secured Direct Lending - The secured direct lending fund intends to float on the Main Market on 15 December raising up to £100m Diversified Oil & Gas— Schedule One now out. $60m to be raised. Expected admission 6 December. Creo Medical Group —UK based medical device company focused on surgical endoscopy, a recent development in minimally invasive surgery. Admission due 7 December. Fundraising details TBA.
Continuing to execute strategy on core focus
03 Oct 16
Q216 results were in line with the upper end of company guidance, with sales of €3.4m and an EBITDA loss of €1.4m. aap Implantate continues to focus on its strategic transition to being a pure trauma company, following the recent sale of its Biomaterials business. As the company continues to drive sales of LOQTEQ in Western Europe and the US alongside the implementation of cost reduction measures, we could see a return to sustained growth.